MedTrace Logo

A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

NCT00808288 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 405

Last updated 2019-02-06

No results posted yet for this study

Summary

To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)

Conditions

  • Pulmonary Disease, Chronic Obstructive
  • Lung Diseases
  • Lung Diseases, Obstructive

Interventions

DRUG

PF-00610355

oral, inhaled, dry powder, 600ug, OD

DRUG

PF - 00610355

oral, inhaled, dry powder, 300ug, OD

DRUG

PF- 00610355

oral, inhaled, dry powder, 100ug, OD

DRUG

Placebo

oral, inhaled, dry powder, placebo, OD

DRUG

Salmeterol

salmeterol, 50ug, BID

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • United States
  • Argentina
  • Bulgaria
  • Croatia
  • Czechia
  • Germany
  • Hungary
  • Poland
  • Slovakia
  • South Africa
  • Spain
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00808288 on ClinicalTrials.gov